Dover has entered right into a definitive settlement to amass Malema Engineering Corp, a US designer and producer of high-precision, mission-critical flow-measurement and control instruments for the biopharmaceutical, semiconductor and industrial sectors.
Image: dizain/Adobe Stock.
Malema’s products will expand Dover’s biopharma single-use manufacturing providing, which already contains Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with facilities in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in income during the full yr 2022.
When the deal closes, Malema will turn into part of the PSG business unit within Dover’s Pumps & Process Solutions segment.
“We see an amazing long-term progress opportunity in the bioprocessing business driven by a robust and growing pipeline of efficient novel biologic medication, biosimilars, protein therapies, non-COVID mRNA vaccines, as well as budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the rising adoption of extra efficient single-use production processes supports a sturdy outlook for our offerings of single-use parts to end-customers. We believe that pairing Malema’s expertise with our current portfolio of single-use pumps for biopharma processing will greatly enhance the accuracy and worth proposition of our solutions to our customers.”
“We are methodically building out our biopharma platform through proactive capacity additions, new product improvement, and opportunistic acquisitions of highly-attractive area of interest component technologies,” stated Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing technology and additional strengthens our sensor portfolio with new proprietary technology. In spmk700 to enticing biopharma functions, we expect strong progress in the semiconductor area on the capacity expansion and re-shoring tailwinds.”
Share